ArticleMedComm2026

Intracranial Efficacy of Crizotinib and Postprogression Therapeutic Strategies in Advanced c-ros Oncogene 1 (ROS1)-Positive Non-Small Cell Lung Cancer (NSCLC), a Multicenter Real-World Study.

Zihua Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.